Tipifarnib Inhibits HRAS-driven Dedifferentiated Thyroid Cancers

Cancer Research - United States
doi 10.1158/0008-5472.can-17-1925
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

New Targeted Molecular Therapies for Dedifferentiated Thyroid Cancer

Journal of Oncology
Oncology
2010English

Abstract LB-A10: Preliminary Results From a Phase 2 Proof of Concept Trial of Tipifarnib in Tumors With HRAS Mutations

2018English

Targeting Autophagy in Thyroid Cancers

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2019English

Identification of a Novel HRAS Variant and Its Association With Papillary Thyroid Carcinoma

Oncology Letters
Cancer ResearchOncology
2018English

Dedifferentiated Liposarcoma

2020English

Pharmacotherapy of Hematologic Malignancies With Tipifarnib

Clinical Medicine. Therapeutics
2009English

Risk Assessment of Radiation‐induced Thyroid Cancers in Belarus

Environmental Management and Health
2000English

The GIST Paradigm: Lessons for Other Kinase-Driven Cancers

Journal of Pathology
Forensic MedicinePathology
2010English

Signification of Forkhead Box A1 (FOXA1) Expression in Thyroid Cancers

Journal of the Egyptian National Cancer Institute
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy